Pyridazin-3(2 H )-one derivatives and their use as PDE4...

Details Pyridazin-3(2 H )-one derivatives and their use as PDE4... Pyridazin-3(2 H )-one derivatives and their use as PDE4...

2011-06-14

2011-06-14

Wilson, James O (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S252040, C544S238000

Reexamination Certificate

active

07960383

ABSTRACT:
The invention relates to new therapeutically useful pyridazin-3(2H)-one derivatives of Formula (I) and to pharmaceutical compositions containing them. These compounds are potent and selective inhibitors of phosphodiesterase 4 (PDE4) and are thus useful in the treatment, prevention or suppression of pathological conditions, diseases and disorders known to be susceptible of being improved by inhibition of PDE4 such as asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis or irritable bowel disease.

REFERENCES:
patent: 5679696 (1997-10-01), Fenton et al.
patent: 5804588 (1998-09-01), Dyke et al.
patent: 5859008 (1999-01-01), Jonas et al.
patent: 5972936 (1999-10-01), Dyke et al.
patent: 6025376 (2000-02-01), Laurent et al.
patent: 6162830 (2000-12-01), Connor et al.
patent: 6204275 (2001-03-01), Friesen et al.
patent: 6699890 (2004-03-01), Schumacher et al.
patent: 7087625 (2006-08-01), Schumacher et al.
patent: 7226930 (2007-06-01), Hopper et al.
patent: 7235579 (2007-06-01), Liu et al.
patent: 7273875 (2007-09-01), Denholm et al.
patent: 7459453 (2008-12-01), Dal Piaz et al.
patent: 7491722 (2009-02-01), Dal Piaz et al.
patent: 7511038 (2009-03-01), Dal Piaz et al.
patent: 2006/0052379 (2006-03-01), Dal Piaz et al.
patent: 2007/0197536 (2007-08-01), Dal Piaz et al.
patent: 2008/0269235 (2008-10-01), Dal Piaz et al.
patent: 2009/0029996 (2009-01-01), Aguilar Izquierdo et al.
patent: 2009/0111819 (2009-04-01), Dal Piaz et al.
patent: 2 225 218 (1973-12-01), None
patent: 1351569 (1974-05-01), None
patent: 405344 (1975-08-01), None
patent: WO 93/07146 (1993-05-01), None
patent: WO 97/15561 (1997-05-01), None
patent: WO 99/06404 (1999-02-01), None
patent: WO 00/24719 (2000-05-01), None
patent: WO 01/46184 (2001-06-01), None
patent: WO 01/94319 (2001-12-01), None
patent: WO 01/94391 (2001-12-01), None
patent: WO 03/097613 (2003-11-01), None
patent: WO 03/097613 (2003-11-01), None
patent: WO 2004/058729 (2004-07-01), None
patent: WO 2005049581 (2004-11-01), None
patent: WO 2005/049581 (2005-06-01), None
patent: WO 2005/123692 (2005-12-01), None
patent: WO 2005/123693 (2005-12-01), None
patent: WO 2007/084560 (2007-07-01), None
patent: WO 2008/107064 (2008-09-01), None
Naldi, et al., Expert Opin. Emerging Drugs (2009) 14(1) 145-163.
Targan, et al., Inflammatory Bowel Disease: From Bench to Bedside, 2nd Edition, pp. 553-571, 2003.
Prehn, et al., J. Clin. Immunol., vol. 21, No. 5, 2001, pp. 357-364.
“Glenmark stops oglemilast (GRC3886) development programme for COPD and asthma with Forest.” May 20, 2010, <http//expresslayout.com/pharmaceuticallitigation/?p=696> Downloaded from the internet May 31, 2010.
V. Dal Piaz, 5-Acyl-6-aryl-4-nitro-3(2H)pyridazinones and Related 4-Amino Compounds: Synthesis and Pharmacological Evaluation, J. Pharmaceutical Sciences, 1991, 341-348, 80(4).
V. Dal Piaz, 4,5-Functionalized 6-phenyl-3(2H)-pyridazinones: synthesis and evaluation of antinociceptive activity, Eur. J..Med. Chem., 1996, 65-70, 31.
L. Constantino, Isoxazolo-[3,4-d]-pyridazin-7-(6H)-one as a Potential Substrate for New Aldose Reductase Inhibitors, J. Med. Chem., 1999, 1894-1900, 42.
U.S. Appl. No. 12/141,712, filed Jun. 18, 2008, Dal Piaz et al.
U.S. Appl. No. 12/247,688, filed Oct. 8, 2008, Dal Piaz et al.
U.S. Appl. No. 12/529,511, filed Nov. 18, 2009, Hereu.
U.S. Appl. No. 10/578,594, filed Feb. 15, 2007, Dal Piaz et al.
U.S. Appl. No. 11/629,527, filed Dec. 14, 2006.
U.S. Appl. No. 10/578,594, filed Jan. 12, 2007.
Barlocco, Daniela et al., Phenylpiperazinylalkylamino Substituted Pyridazinones as Potent α1 Adrenoceptor Antagonists, J. Med. Chem., 44:2403-2410 (2001).
Baumer, et al., Inflammation & Allergy—Drug Targets, vol. 6, No. 1, Mar. 2007, pp. 17-26 (10).
Bulka E., et al., Zeitschrift Für Chemie, 5(10):374-375 (1965).
Caplus Abstract for SU 405344, Accession No. 1976:4988 dated May 12, 1984.
Calverley et al., The Lancet, 374: 685-694 (2009).
Ciciani, Giovanna et al., “Synthesis and Evaluation of In Vitro Antitumor Activity of Some Substituted 5-Pyridazinyl-Styrylketones,” Il Farmaco, 46 (7,8)873-885 (1991).
Diaz-Granados, Natalia et al., “Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity,” American Journal of Pathology, 156(6):2169-2177 (2000).
Dyke, Hazel J., et al., “The therapeautic potential of PDE4 inhibitors,” Exp. Opin. Invest. Drugs, 8(9):1301-1325 (1999).
English-language abstract for W0 97/15561 (May 1, 1997).
English-language machine translation of DE 2 225 218 from esp@cenet database (Dec. 20, 1973).
Entry No. 3603 for Emorfazone in Merck Index (1994).
Essayan, David M., “Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation,” Biochemical Pharmacology, 57:965-973 (1999).
European Respiratory Society, Feb. 13, 2007, http://www.netocopd.com/currentaffairsnews/list751—item17680.aspx, downloaded Jan. 16, 2008.
Fabbri et al., The Lancet, 374: 695-703 (2009).
Gilhar, A., et al., “Antiproliferative effect of pentoxifylline on psoriatic and normal epidermis,” Acta Derm Venereol, 76:437-441 (1996).
Griffiths, et al., British J. of Dermatology, 147:299-307 (2002).
Hanifin, Jon M., et al., “Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis,” Journal of Investigative Dermatology, 107(1):51-56 (1996).
Hartmann, Gunther et al., “Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice,” Journal of Pharmacology and Experimental Therapeutics, 292(1):22-30 (2000).
Implications for Rheumatoid Arthritis http://www.medscape.com/viewarticle/464104—4, downloaded Jul. 8, 2007.
International Search Report for PCT/EP2008/001080 dated May 16, 2008.
International Search Report for PCT/EP2004/012604, dated Feb. 11, 2005.
International Search Report for PCT/EP2003/014772 dated Mar. 10, 2004.
International Search Report for PCT/EP2009/008794 dated Feb. 25, 2010.
International Search Report for PCT/EP2005/006712 dated Nov. 16, 2005.
International Search Report for PCT/EP2005/006304 dated Nov. 7, 2005.
International Search Report for PCT/EP2003/05056 dated Oct. 2, 2003.
Lipworth, Lancet, 365:167-175 (2005).
MacKenzie, “Phosphodiesterase 4 cAMP phosphodiesterasesas targets for novel anti-inflammatory therapeutics,” Alergology International, 53:101-110 (2004).
Marks, Andrew R., “Drugs in trials for asthma, alzheimer's and chronic lung disease may cause heart disease,” Columbia University Medical Center press release, http://www.cumc.columbia.edu
ews/press—releases/Marks—Cell.html, downloaded Jul. 9, 2007.
Nicholson, C. David, et al., “Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes,” TiPS, 12:19-27 (1991).
Notice of Allowance dated Mar. 19, 2008 in U.S. Appl. No. 10/513,219.
Notice of Allowance dated Nov. 28, 2008 in U.S. Appl. No. 10/578,594.
Notice of Allowance dated Jul. 9, 2008 in U.S. Appl. No. 10/539,821.
Nycomed, Press Release, Nycomed files European marketing authorization application for Daxas® in COPD, (Mar. 8, 2009).
Nycomed, Press Release, Nycomed announced FDA filing for Daxas® in COPD, (Jul. 20, 2009).
Nyman, U., et al., “Amelioration of collagen II-induced arthritis in rats by the type IV phosphodiesterase inhibitor rolipram,” Clin. Exp. Immunol, 108:415-419 (1997).
Office Action dated May 15, 2008, in U.S. Appl. No. 10/578,594.
Office Action dated Nov. 27, 2007 in U.S. Appl. No. 10/513,219.
Office Action dated Nov. 20, 2006 in U.S. Appl. No. 10/513,219.
Office Action dated Jul. 2, 2007 in U.S. Appl. No. 10/513,219.
Office Action dated Jul. 18, 2007 in U.S. Appl. No. 10/513,219.
Office Action dated Feb. 4, 2008 in U.S. Appl. No. 10/539,821.
Office Action dated Sep. 19, 2007 in U.S. Appl. No. 10/539,821.
Of

Affiliated with

Also associated with

Rating

Pyridazin-3(2 H )-one derivatives and their use as PDE4... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyridazin-3(2 H )-one derivatives and their use as PDE4..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridazin-3(2 H )-one derivatives and their use as PDE4... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2652470